Salud financiera de hoja de balance de Cara Therapeutics
Salud financiera controles de criterios 5/6
Cara Therapeutics tiene un patrimonio de los accionistas total de $57.1M y una deuda total de $37.1M, lo que sitúa su ratio deuda-patrimonio en 65%. Sus activos y pasivos totales son $125.8M y $68.8M respectivamente.
Información clave
65.0%
Ratio deuda-patrimonio
US$37.08m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$100.76m |
| Patrimonio | US$57.09m |
| Total pasivo | US$68.76m |
| Activos totales | US$125.84m |
Actualizaciones recientes sobre salud financiera
We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Feb 16
Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?
Oct 25Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?
Jul 20We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth
Feb 06Recent updates
We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Feb 16The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%
Dec 19News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts
Nov 04Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?
Oct 25Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?
Jul 20Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper
Jun 04News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat
Mar 11Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates
Feb 15We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth
Feb 06We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow
Oct 18Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
Sep 28Cara Therapeutics hires new finance chief
Sep 12Cara Therapeutics: All Eyes On Korsuva Launch Metrics
Sep 01Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
Aug 19Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M
Aug 08Calls A Much Safer Way To Buy Cara Therapeutics
Jun 24We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Jun 15Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts
May 12Taking A (Speculative) Position In Cara Therapeutics
Mar 21Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth
Mar 09Cara Therapeutics: De-Risked And Extremely Attractive
Dec 25Checking Back In On Cara Therapeutics
Nov 01Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA
Aug 21The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically
Aug 15Cara Therapeutics: 200% Upside Possible With FDA Approval
Aug 11Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive
Jul 19It's Unlikely That The CEO Of Cara Therapeutics, Inc. (NASDAQ:CARA) Will See A Huge Pay Rise This Year
May 28Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($116.2M) de CARA superan a sus pasivos a corto plazo ($25.6M).
Pasivo a largo plazo: Los activos a corto plazo de CARA ($116.2M) superan a sus pasivos a largo plazo ($43.2M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: CARA tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de CARA ha crecido de 0% a 65% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: CARA tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: CARA dispone de suficiente cash runway para 2.3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 8.9% cada año.